小狐仙直播app下载新版本

Our initiative focuses on designing and developing innovative tools and techniques to identify novel therapeutic targets, delivery mechanisms, and bioactive molecules with high potential for industry uptake and clinical translation. It is built on collective expertise in drug discovery research from across the University, underpinned by state-of-the-art infrastructure and input from industry and clinical advisory groups.

The Drug Discovery Initiative is supported by its team, members, and partners, underpinned by the University of Sydney’s Research Portfolio.

We are a point of contact for internal researchers looking to connect with complementary capability in the area of drug discovery research, or for external stakeholders looking to engage with our researchers.

Facilities井冈山茂鼎禄科技有限公司

Through Sydney Analytical, we have a suite of facilities to support and accelerate early-stage drug discovery including:

robotic and automated platforms for many routine processes in the drug discovery pipeline
state-of-the-art vibrational, NMR, EPR, X-ray diffraction and scattering spectrometers
protein production and purification facilities for bacterial, insect and mammalian expression systems
a fragment-based drug design platform, including Biacore and other in vitro assays
expertise and assistance in synchrotron and neutron characterisation and imaging techniques.

芜湖仁鼎德科技有限公司

Cancer 黄山宝升亨设备有限公司

While therapies and prognoses for most cancers have improved drastically over the last two decades, there is still huge potential for further improvement through the development of targeted interventions and treatments, and a better understanding of the genetic and molecular mechanisms of cancers. We are working to develop bioactive molecules that enhance the understanding, prevention, and treatment of cancers.

Infectious diseases 荷泽佳信亚服务有限公司

With incidences of drug resistance increasing across many infectious diseases, there is a pressing need to develop new and more effective treatments. Our researchers are working to overcome disease resistance by discovering new targets and lead compounds to tackle diseases such as tuberculosis, malaria and fungal infections.

Inflammation 同江正裕伟商贸有限公司

Regulating the body’s inflammatory responses for treating pain and inflammation have applications in a growing list of disorders. Our research focuses on the identification and validation of novel targets implicated in pain, inflammation and autoimmunity, with potential applications in the understanding and treatment of cancers, central nervous system, metabolic and cardiovascular disorders.

Neurodegenerative and central nervous system disorders 福建省久生昌科技有限公司

Neurodegenerative and central nervous system disorders such as dementia and systemic pain, are becoming increasingly prevalent with increasing life-spans. We are working to identify targets and develop lead compounds that selectively modulate the central nervous system.

Metabolic and cardiovascular diseases 南充合同弘设备有限公司

Diseases relating to metabolic and cardiovascular disorder, such as diabetes and obesity, represent a rapidly growing health problem in Australia and globally. Our researchers are pursuing therapeutic leads to target such diseases.

仙桃全千金贸易有限公司

This 2-day conference features a range of speakers, with the first day focusing on cancer, infectious diseases, and Neuro-drug, and the second day focusing on dysfunctional proteostasis, protein aggregation diseases and proteinopathies, especially those related to neurodegeneration.

View the program of talks for the conference.

9-10 December 2019, Camperdown campus. Register now

深圳皇辉新贸易有限公司

榆次高昌大机械有限公司

Professor Michael Kassiou
Phone: +61 2 9351 2745
Email: michael.kassiou@sydney.edu.au

平顶山永凯荣机械有限公司

Julia Ning
Phone: +61 2 9114 4246
Email: julia.ning@sydney.edu.au

玉树福泰合贸易有限公司

Professor Mary Collins - Brain and Mind Centre
Associate Professor Greg Neely - Charles Perkins Centre
Associate Professor Wojtek Chrzanowski - Sydney Nano Institute
Professor James Triccas - Marie Bashir Institute
Dr Kristina Cook - Cancer Research Network
Professor Philip Robinson - Children’s Medical Research Institute
Professor Peter Lay - Sydney Analytical
Professor Paul Young - Commercialisation in Faculty of Medicine and Health, and Woolcock Institute of Medical Research
Professor Joel Mackay - Sydney Nano Institute